Anti-HER2/neu peptide producing vector system for biologic therapy - Is it possible to mass-produce the peptide?

Byeongwoo Park, Ki Suk Kim, Min Kyu Heo, Kyong Sik Lee, Eunkyung Kim, Kyung Sup Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A humanized monoclonal antibody against HER2 has been using in a clinical setting and has been shown to possess therapeutic properties. A mimetic peptide against HER2 was also reported to bind to the HER2 receptor with some therapeutic potential. Based on a previous report and the sequence of Herceptin, we designed oligonucleotides of anti-HER2 mimetic peptides, named V2 and V3 peptides, in order to develop a peptide-producing vector system for biologic therapy against HER2-overexpressing cancers. We also adopted the sequence of a previously reported mimetic peptide, V1 (Park BW et al. Nat. Biotechnol, 2000, 18:194-198), as a reference peptide. We examined the effects of the V2 and V3 peptides against the HER2-overexpressing cell lines, SK-BR-3 and T6-17. Transient transfection of the construct expressing V1 and V2 inhibited cell proliferation in HER2-overexpressing cell lines by 20 - 30%, but had no effect on the HER2-negative NIH3T3 cells. The proliferation inhibition shown by V2 was slightly better than that shown by V1. Recombinant peptides V2 and V3 were produced on a large scale in an E. coli system, and the V2 peptide showed anti-HER2-specific tumor cell proliferation inhibition of 10% to 30%. Current results suggest that anti-HER2 mimetic peptides, overexpressed by a constitutive promoter or produced in an E. coli system, could specifically inhibit the proliferation of HER2-expressing cancer cells. Further efforts to augment the biologic specificity and efficacy and to develop new technologies for the purification of the peptide from the E coli system are needed.

Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalYonsei Medical Journal
Volume44
Issue number1
DOIs
Publication statusPublished - 2003 Jan 1

Fingerprint

Biological Therapy
Peptides
Escherichia coli
Cell Proliferation
Antibodies, Monoclonal, Humanized
Cell Line
Neoplasms
Oligonucleotides
Transfection
Technology

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{22379a3535a14310844bbf458e810e63,
title = "Anti-HER2/neu peptide producing vector system for biologic therapy - Is it possible to mass-produce the peptide?",
abstract = "A humanized monoclonal antibody against HER2 has been using in a clinical setting and has been shown to possess therapeutic properties. A mimetic peptide against HER2 was also reported to bind to the HER2 receptor with some therapeutic potential. Based on a previous report and the sequence of Herceptin, we designed oligonucleotides of anti-HER2 mimetic peptides, named V2 and V3 peptides, in order to develop a peptide-producing vector system for biologic therapy against HER2-overexpressing cancers. We also adopted the sequence of a previously reported mimetic peptide, V1 (Park BW et al. Nat. Biotechnol, 2000, 18:194-198), as a reference peptide. We examined the effects of the V2 and V3 peptides against the HER2-overexpressing cell lines, SK-BR-3 and T6-17. Transient transfection of the construct expressing V1 and V2 inhibited cell proliferation in HER2-overexpressing cell lines by 20 - 30{\%}, but had no effect on the HER2-negative NIH3T3 cells. The proliferation inhibition shown by V2 was slightly better than that shown by V1. Recombinant peptides V2 and V3 were produced on a large scale in an E. coli system, and the V2 peptide showed anti-HER2-specific tumor cell proliferation inhibition of 10{\%} to 30{\%}. Current results suggest that anti-HER2 mimetic peptides, overexpressed by a constitutive promoter or produced in an E. coli system, could specifically inhibit the proliferation of HER2-expressing cancer cells. Further efforts to augment the biologic specificity and efficacy and to develop new technologies for the purification of the peptide from the E coli system are needed.",
author = "Byeongwoo Park and Kim, {Ki Suk} and Heo, {Min Kyu} and Lee, {Kyong Sik} and Eunkyung Kim and Kim, {Kyung Sup}",
year = "2003",
month = "1",
day = "1",
doi = "10.3349/ymj.2003.44.1.58",
language = "English",
volume = "44",
pages = "58--64",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Anti-HER2/neu peptide producing vector system for biologic therapy - Is it possible to mass-produce the peptide? / Park, Byeongwoo; Kim, Ki Suk; Heo, Min Kyu; Lee, Kyong Sik; Kim, Eunkyung; Kim, Kyung Sup.

In: Yonsei Medical Journal, Vol. 44, No. 1, 01.01.2003, p. 58-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-HER2/neu peptide producing vector system for biologic therapy - Is it possible to mass-produce the peptide?

AU - Park, Byeongwoo

AU - Kim, Ki Suk

AU - Heo, Min Kyu

AU - Lee, Kyong Sik

AU - Kim, Eunkyung

AU - Kim, Kyung Sup

PY - 2003/1/1

Y1 - 2003/1/1

N2 - A humanized monoclonal antibody against HER2 has been using in a clinical setting and has been shown to possess therapeutic properties. A mimetic peptide against HER2 was also reported to bind to the HER2 receptor with some therapeutic potential. Based on a previous report and the sequence of Herceptin, we designed oligonucleotides of anti-HER2 mimetic peptides, named V2 and V3 peptides, in order to develop a peptide-producing vector system for biologic therapy against HER2-overexpressing cancers. We also adopted the sequence of a previously reported mimetic peptide, V1 (Park BW et al. Nat. Biotechnol, 2000, 18:194-198), as a reference peptide. We examined the effects of the V2 and V3 peptides against the HER2-overexpressing cell lines, SK-BR-3 and T6-17. Transient transfection of the construct expressing V1 and V2 inhibited cell proliferation in HER2-overexpressing cell lines by 20 - 30%, but had no effect on the HER2-negative NIH3T3 cells. The proliferation inhibition shown by V2 was slightly better than that shown by V1. Recombinant peptides V2 and V3 were produced on a large scale in an E. coli system, and the V2 peptide showed anti-HER2-specific tumor cell proliferation inhibition of 10% to 30%. Current results suggest that anti-HER2 mimetic peptides, overexpressed by a constitutive promoter or produced in an E. coli system, could specifically inhibit the proliferation of HER2-expressing cancer cells. Further efforts to augment the biologic specificity and efficacy and to develop new technologies for the purification of the peptide from the E coli system are needed.

AB - A humanized monoclonal antibody against HER2 has been using in a clinical setting and has been shown to possess therapeutic properties. A mimetic peptide against HER2 was also reported to bind to the HER2 receptor with some therapeutic potential. Based on a previous report and the sequence of Herceptin, we designed oligonucleotides of anti-HER2 mimetic peptides, named V2 and V3 peptides, in order to develop a peptide-producing vector system for biologic therapy against HER2-overexpressing cancers. We also adopted the sequence of a previously reported mimetic peptide, V1 (Park BW et al. Nat. Biotechnol, 2000, 18:194-198), as a reference peptide. We examined the effects of the V2 and V3 peptides against the HER2-overexpressing cell lines, SK-BR-3 and T6-17. Transient transfection of the construct expressing V1 and V2 inhibited cell proliferation in HER2-overexpressing cell lines by 20 - 30%, but had no effect on the HER2-negative NIH3T3 cells. The proliferation inhibition shown by V2 was slightly better than that shown by V1. Recombinant peptides V2 and V3 were produced on a large scale in an E. coli system, and the V2 peptide showed anti-HER2-specific tumor cell proliferation inhibition of 10% to 30%. Current results suggest that anti-HER2 mimetic peptides, overexpressed by a constitutive promoter or produced in an E. coli system, could specifically inhibit the proliferation of HER2-expressing cancer cells. Further efforts to augment the biologic specificity and efficacy and to develop new technologies for the purification of the peptide from the E coli system are needed.

UR - http://www.scopus.com/inward/record.url?scp=0037296884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037296884&partnerID=8YFLogxK

U2 - 10.3349/ymj.2003.44.1.58

DO - 10.3349/ymj.2003.44.1.58

M3 - Article

C2 - 12619176

AN - SCOPUS:0037296884

VL - 44

SP - 58

EP - 64

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -